Completed PHASE2 INTERVENTIONAL NCT00337246

Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) With or Without Rituximab in Previously Treated Chronic Lymphocytic Leukemia

Sponsor: Cancer Research UK

Conditions Leukemia

Interventions cyclophosphamide fludarabine phosphate mitoxantrone hydrochloride rituximab

Updated 5 times since 2017 Last updated: Aug 1, 2013 Started: Jul 31, 2005 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Leukemia, this trial is completed. The trial is conducted by Cancer Research UK and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Research UK

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Airdrie, United Kingdom , Birmingham, United Kingdom , Blackpool, United Kingdom , Canterbury, United Kingdom , Cardiff, United Kingdom , Carshalton, United Kingdom , Dartford Kent, United Kingdom , Gillingham Kent, United Kingdom , Leeds, United Kingdom , Leicester, United Kingdom and 6 more locations